NIH Reluctant To “March In”: Collins Suggests Authority Not Intended To Address Pricing Concerns

Legislators are urging the National Institutes of Health to use intellectual property levers to put pressure on prescription drug pricing. NIH has historically been reluctant to play the role of the price police – and it still is.